Data on the dural invasiveness of @entity977 have been correlated to the expression of matrix metalloproteinases (e.g. @entity1495 ). @entity563 proteases have not yet been investigated in @entity1 @entity977 . In this study, @entity982 -embedded material from 84 @entity1 @entity977 ( @entity2012 n=18, @entity699 n=21, @entity2013 n=18, thyroid-stimulating hormone-secreting @entity652 n=1, nonsecreting @entity652 n=26) and 9 nontumourous anterior pituitary lobes (obtained from @entity1 with @entity263 ) was immunohistochemically analysed for expression of @entity1476 , @entity1495 , @entity1552 ( @entity1552 ), @entity2290 ( @entity2290 ), @entity10431 ( @entity10431 ), tissue-type plasminogen activator (tPA), @entity2289 ( @entity2289 ), and @entity650 ( @entity650 ). Cavernous sinus invasion was determined by assessment of preoperative magnetic resonance imaging and intraoperative inspection (invasive n=50, noninvasive n=34). In @entity977 , reactions were positive (diffuse expression) to @entity1476 (74% of cases), @entity1495 (49%), @entity1552 (88%), @entity2290 (89%), @entity10431 (90%), tPA (69%), and @entity2289 (87%). A weak expression of @entity650 was found in 12% of the @entity652 . All reactions were positive (focal expression) in every sample of anterior lobe tissue, except for @entity2290 (negative in 3 out of 9 cases), and @entity650 (faintly positive in 5 out of 8 cases). @entity652 showed remarkably greater expression of @entity2290 than anterior lobe tissue (Chi-square P<0.05). Nonsecreting @entity652 exhibited a stronger tendency towards overexpression of @entity2290 in invasive @entity5 when compared to noninvasive @entity652 (Chi-square P=0.053). We found no correlation of @entity1495 expression and @entity5 invasion. @entity1552 was overexpressed in noninvasive as compared to invasive @entity652 (Chi-square P<0.05). The interrelationship between MMPs and @entity563 proteinases in @entity977 remains to be elucidated. From our data, a correlation between @entity650 and an activation of @entity1495 cannot be proven. The @entity2290 -system may, however, play a role in dural invasion of @entity977 .

Expression of @entity563 proteases and metalloproteinases in XXXX @entity977 and anterior pituitary lobe tissue.

@entity1 :: ('9606', 'Species') :: ['human', 'patients'] @entity1552 :: ('7077', 'Gene') :: ['TIMP-2', 'tissue inhibitor of metalloproteinases-2'] @entity650 :: ('3569', 'Gene') :: ['IL-6', 'interleukin-6'] @entity2013 :: ('MESH:D015175', 'Disease') :: ['prolactinoma'] @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer'] @entity10431 :: ('5329', 'Gene') :: ['uPA receptor', 'uPAR'] @entity1476 :: ('4313', 'Gene') :: ['MMP-2'] @entity2289 :: ('5054', 'Gene') :: ['plasminogen activator inhibitor-1', 'PAI-1'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour', 'tumours'] @entity699 :: ('MESH:D003480', 'Disease') :: ["Cushing's disease"] @entity2012 :: ('MESH:D000172', 'Disease') :: ['acromegaly'] @entity982 :: ('MESH:D010232', 'Chemical') :: ['paraffin'] @entity977 :: ('MESH:D010911', 'Disease') :: ['pituitary adenomas'] @entity1495 :: ('4318', 'Gene') :: ['MMP-9'] @entity563 :: ('CHEBI:17822', 'Chemical') :: ['serine', 'Serine'] @entity652 :: ('MESH:D000236', 'Disease') :: ['adenomas', 'adenoma', 'Adenomas'] @entity2290 :: ('5328', 'Gene') :: ['urokinase-type plasminogen activator', 'uPA']
@entity1 :: (9606,Species) :: ['human']
